Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
- 22 Downloads
We report a patient with HER2-positive breast cancer with extensive bone metastasis who achieved excellent and durable response with oral etoposide.
KeywordsHER2-positive breast cancer Oral etoposide Response
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Johnston SRD, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: alternative. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:741–8.CrossRefGoogle Scholar
- 6.Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:855–61.Google Scholar